Cholera kills between 25% and 50% of people who don’t receive treatment, making it one of the most rapidly fatal infectious diseases. With proper rehydration therapy, that fatality rate drops below 1%. The enormous gap between those two numbers defines cholera’s paradox: it is both extremely deadly and almost entirely survivable, depending on access to basic medical care.
How Fast Cholera Can Kill
Cholera can be fatal within hours of the first symptoms appearing. In severe cases, sometimes called cholera gravis, dangerously low blood pressure can develop within hours of onset. The disease kills through massive fluid loss. The bacterium produces a toxin that hijacks the cells lining your intestines, forcing them to pump out water, sodium, and other electrolytes at an extraordinary rate. A person with severe cholera can lose liters of fluid per hour through watery diarrhea, rapidly draining the body’s blood volume.
As fluid drains out, blood pressure plummets. The heart races trying to compensate. Urine output drops. Skin becomes cold and loses its elasticity. Breathing becomes deep and labored as the blood turns acidic. Without fluid replacement, the cardiovascular system collapses. There is even a rare variant of cholera where fluid accumulates so rapidly inside the intestines that circulatory collapse and death occur before diarrhea even begins.
Who Faces the Highest Risk
Children under five have the highest cholera mortality rates of any age group, and that rate has actually been increasing over recent decades. Globally, cholera death rates are nearly five times higher in people under 20 than in adults over 20. Young children are especially vulnerable because chronic malnutrition, which affects roughly half of children under five in the hardest-hit regions, weakens their ability to survive the fluid loss. Their smaller bodies also have less margin for dehydration before organs begin to fail.
Blood type plays a surprisingly large role. Having type O blood doesn’t make you more likely to catch cholera, but it dramatically increases severity. During Peru’s 1991 cholera epidemic, people with type O blood were eight times more likely to be hospitalized with severe disease. Lab research has shown why: the cholera toxin binds more tightly and in more orientations to type O blood group markers on intestinal cells, triggering a stronger fluid-loss response than in people with type A or B blood.
Malnutrition, lack of stomach acid (which normally helps kill bacteria before they reach the intestines), and weakened immunity from other infections all compound the risk further.
Why Treatment Works So Well
The core of cholera treatment is remarkably simple: replace the lost fluid and electrolytes faster than the body loses them. Oral rehydration solution, a precise mixture of salts, sugar, and water, is the primary tool. A meta-analysis of community programs found that promoting oral rehydration reduced diarrheal deaths by 69%. At full coverage, the estimated reduction would reach 93%.
This is why the gap between treated and untreated cholera is so stark. The disease doesn’t damage organs directly or destroy tissue the way many fatal infections do. It kills through dehydration alone. If you can keep a patient hydrated long enough for the infection to run its course (typically a few days), survival is almost guaranteed. Severe cases need intravenous fluids, but the principle is the same.
The Global Picture Right Now
Cholera is surging worldwide. In 2024, reported deaths rose 50% compared to the previous year, with more than 6,000 people killed by a disease that has a straightforward treatment. Sixty countries reported cases in 2024, up from 45 the year before. Africa bears the heaviest burden, and the continent’s case fatality ratio climbed from 1.4% in 2023 to 1.9% in 2024, reflecting gaps in access to care rather than any change in the disease itself.
In January 2026 alone, the WHO reported nearly 17,000 new cases across 19 countries and 182 deaths, a 20% increase in fatalities from the previous month. The African region continued to register the highest case numbers, followed by the Eastern Mediterranean and South-East Asia.
How Vaccines Reduce the Toll
Oral cholera vaccines provide moderate but meaningful protection. A two-dose regimen averages about 58% efficacy over three years in clinical trials. In real-world use across outbreaks in Mozambique, Zanzibar, Guinea, Haiti, and India, effectiveness has averaged around 76%. A single dose offers roughly 40% protection, holding steady at two years.
Vaccines are less effective in young children in low-income countries than in adults or in wealthier settings. Malnutrition, interference from maternal antibodies, and prior exposure to other gut infections all blunt the immune response. This is particularly frustrating because children under five are the group most likely to die from cholera.
What Makes Cholera So Dangerous in Practice
Cholera’s lethality is less about the biology of the bacterium and more about the circumstances surrounding it. The disease thrives where clean water and sanitation are absent, which are the same places that tend to lack the clinics, rehydration supplies, and trained health workers needed to treat it. A case of cholera in a hospital with IV fluids on hand is rarely fatal. The same case in a displaced persons camp without clean water or nearby care can be a death sentence within hours.
That 1% fatality rate with treatment is an average across well-resourced settings. In active outbreaks in under-resourced areas, the real-world fatality rate climbs significantly higher, as Africa’s rising case fatality ratio demonstrates. The lethality of cholera, in other words, is a measure of healthcare access as much as it is a measure of the disease.